<p>Nektar Therapeutics（纳斯达克股票代码：NKTR - 获取免费报告）于周四发布了季度财报。这家生物制药公司报告的每股收益（EPS）为（$1.78），超出市场共识预期的（$2.69）$0.91，FiscalAI 报道。Nektar Therapeutics 的净利润率为负的 192.87%，股本回报率为负的 456.53%。该公司在本季度的收入为 2181 万美元，而分析师的预期为 1044 万美元。</p>
<p>获取 <strong>Nektar Therapeutics</strong> 的提醒：</p>
<h2>Nektar Therapeutics 股价下跌 4.1%</h2>
<ul>
<li>3 只具有爆炸性增长趋势的生物科技股票</li>
</ul>
<p>Nektar Therapeutics 的股票在周四交易中下跌了$2.97，报$70.36。该公司的交易量为 963,157 股，而其平均交易量为 1,172,891 股。该股票的市值为 14.3 亿美元，市盈率为-8.83，贝塔值为 1.17。Nektar Therapeutics 的 1 年最低价为$6.45，1 年最高价为$75.67。该公司的 50 日简单移动平均线为$52.34，200 日简单移动平均线为$52.62。</p>
<h2>Nektar Therapeutics 的内部买卖</h2>
<p>在其他新闻中，内部人士 Jonathan Zalevsky 于 1 月 20 日（星期二）出售了该公司 3867 股股票。股票以平均价格$35.67 出售，总交易额为$137,935.89。交易完成后，该内部人士直接持有公司 21,354 股，价值$761,697.18。这笔交易代表其持股减少了 15.33%。该交易已在 SEC 的备案中披露，相关信息可在 SEC 网站上找到。此外，首席执行官 Howard W. Robin 于 2 月 18 日（星期三）出售了 423 股公司的股票。股票以平均价格$73.00 出售，总价值为$30,879.00。交易完成后，首席执行官持有公司 75,489 股，价值$5,510,697。这代表其持股减少了 0.56%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士已出售 4470 股公司股票，价值$181,955。公司内部人士持有公司股票的 5.25%。</p>
<h2>Nektar Therapeutics 的机构交易</h2>
<ul>
<li>生物科技催化剂警报：NKTR、CDTX 和 WGS 大幅上涨</li>
</ul>
<p>对冲基金最近对该公司的持仓进行了调整。Virtu Financial LLC 在第四季度购买了 Nektar Therapeutics 的新头寸，价值约为 584,000 美元。Invesco Ltd.在第四季度将其在 Nektar Therapeutics 的持股增加了 106.3%。Invesco Ltd.现在拥有 468,159 股该生物制药公司的股票，价值$19,794,000，此前在上个季度又购买了 241,262 股。Creek Drive Management Group LLC 在第四季度购买了 Nektar Therapeutics 的新头寸，价值约为 7,843,000 美元。KVP Capital Advisors LP 在第四季度购买了 Nektar Therapeutics 的新头寸，价值约为 1,137,000 美元。最后，XTX Topco Ltd 在第四季度将其在 Nektar Therapeutics 的持股增加了 22.0%。XTX Topco Ltd 现在拥有 7,196 股该生物制药公司的股票，价值$304,000，此前在上个季度又收购了 1,299 股。机构投资者和对冲基金持有公司 75.88% 的股票。</p>
<h2>华尔街分析师的看法</h2>
<p>NKTR 已成为几份分析师报告的主题。HC Wainwright 在 2 月 10 日（星期二）的研究报告中将 Nektar Therapeutics 的目标股价从$135.00 上调至$165.00，并给予该公司 “买入” 评级。Piper Sandler 在 1 月 26 日（星期一）的研究报告中重申了 “增持” 评级，并设定了 Nektar Therapeutics 的目标股价为$105.00。Jefferies Financial Group 在 12 月 17 日（星期三）的研究报告中重申了对 Nektar Therapeutics 的 “买入” 评级。Weiss Ratings 在 12 月 29 日（星期一）的研究报告中重新发布了对 Nektar Therapeutics 的 “卖出（e+）” 评级。最后，BTIG Research 在 2 月 10 日（星期二）的研究报告中将 Nektar Therapeutics 的目标股价从$118.00 上调至$151.00，并给予该公司 “买入” 评级。八位投资分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat，该公司目前的平均评级为 “适度买入”，共识目标价为$126.29。</p>
<ul>
<li>Nektar 因药物试验数据上涨 157%——还能更高吗？</li>
</ul>
<p><strong>查看我们最新的 NKTR 股票分析</strong></p>
<h2>关于 Nektar Therapeutics 的热门头条</h2>
<p>以下是本周影响 Nektar Therapeutics 的主要新闻故事：</p>
<ul>
<li>中性情绪：2025 财年第四季度业绩：Nektar 报告截至 2025 年 12 月 31 日的现金及可交易证券为 2.458 亿美元，较去年同期的 2.691 亿美元下降——这一下降突显了公司在推进项目时流动性有限，但本身并不构成灾难。Nektar Therapeutics 发布 2025 年第四季度及全年财务业绩</li>
<li>消极情绪：集体诉讼已提起：在加州北区提起了一项证券集体诉讼，指控在 2025 年 2 月 26 日至 2025 年 12 月 15 日期间存在虚假陈述——这可能导致未来的潜在责任、调查风险、管理分心和声誉损害。Pomerantz 律师事务所宣布对 Nektar Therapeutics, Inc.及部分高管提起集体诉讼 - NKTR</li>
<li>消极情绪：多家律师事务所和调查人员正在招募投资者并展开调查（Glancy, Faruqi, Bernstein, Robbins, Rosen, Frank R. Cruz 等），加大了卖压，并表明诉讼活动将持续。这些通知通常会导致首席原告竞争和诉讼成本增加。代表性通知：对 Nektar Therapeutics (NKTR) 的证券欺诈调查已宣布</li>
<li>消极情绪：关于诉讼潮的持续宣传：多家律师事务所（Faruqi, Bernstein, Robbins, Rosen）发出的额外提醒和警报使这一问题对零售和机构持有者保持可见，可能延长波动性。示例：Pomerantz 律师事务所公告 Faruqi &amp; Faruqi 提醒</li>
<li>消极情绪：市场评论：分析师和媒体解释了股价下跌的原因，并将其与诉讼和先前的临床披露联系起来（投资者正在仔细审查），进一步强化了消极情绪。为什么 Nektar Therapeutics (NKTR) 的股票下跌了 8.32%</li>
</ul>
<h2>Nektar Therapeutics 公司简介</h2>
<p>(获取免费报告)</p>
<p>Nektar Therapeutics（纳斯达克：NKTR）是一家生物制药公司，致力于通过其专有的化学和免疫学平台发现和开发新型药物候选者。该公司专注于聚合物结合技术，使现有药物的长效版本得以创造，并专注于 T 细胞调节疗法，旨在利用身体的免疫系统治疗癌症和其他严重疾病。</p>
<p>Nektar 的产品组合和管道包括一系列临床阶段和合作项目。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票超过 Nektar Therapeutics</li>
<li>20 万亿美元的发现隐藏在海洋之下</li>
<li>历史上最大的 IPO 即将到来</li>
<li>特朗普的新行政命令 - 退休账户将迎来重大变化</li>
<li>今天只有 500 人……</li>
<li>中央银行刚刚做了一件自 1967 年以来未曾做过的事情</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TktUUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TktUUg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在 Nektar Therapeutics 吗？</h2>
<p>在考虑 Nektar Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Nektar Therapeutics 并不在名单上。</p>
<p>虽然 Nektar Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

医药突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

标普全球医疗股指数 ETF - iShares

动态生物技术与基因组 ETF - Invesco

内克塔治疗

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

纽交所高增长板生物技术指数 ETF - First Trust

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 3 倍做多 - Direxion

<p>内克塔治疗（NASDAQ:NKTR）报告每股收益为（$1.78），超出预期的（$2.69）$0.91。公司实现收入 2181 万美元，超过预测的 1044 万美元。尽管净利润率为负的 192.87%，股本回报率为-456.53%，但股票下跌 4.1%，报 70.36 美元。分析师对该股的共识评级为 “适度买入”，目标价为 126.29 美元。内部交易活动包括首席执行官霍华德·W·罗宾和内部人士乔纳森·扎列夫斯基的股票出售，而机构持股比例为 75.88%</p>

<p>Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.69) by $0.91, FiscalAI reports. Nektar Therapeutics had a negative net margin of 192.87% and a negative return on equity of 456.53%. The firm had revenue of $21.81 million during the quarter, compared to analysts' expectations of $10.44 million.</p>
<div class="lb-trans"><p>Nektar Therapeutics（纳斯达克股票代码：NKTR - 获取免费报告）于周四发布了季度财报。这家生物制药公司报告的每股收益（EPS）为（$1.78），超出市场共识预期的（$2.69）$0.91，FiscalAI 报道。Nektar Therapeutics 的净利润率为负的 192.87%，股本回报率为负的 456.53%。该公司在本季度的收入为 2181 万美元，而分析师的预期为 1044 万美元。</p>
</div><p>Get <strong>Nektar Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Nektar Therapeutics</strong> 的提醒：</p>
</div><h2>Nektar Therapeutics Trading Down 4.1%</h2>
<div class="lb-trans"><h2>Nektar Therapeutics 股价下跌 4.1%</h2>
</div><ul>
<li>3 Bullish Biotech Stocks With Explosive Growth Trends</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只具有爆炸性增长趋势的生物科技股票</li>
</ul>
</div><p>Nektar Therapeutics stock traded down $2.97 during trading on Thursday, hitting $70.36. The company had a trading volume of 963,157 shares, compared to its average volume of 1,172,891. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of -8.83 and a beta of 1.17. Nektar Therapeutics has a 1-year low of $6.45 and a 1-year high of $75.67. The company's 50 day simple moving average is $52.34 and its 200-day simple moving average is $52.62.</p>
<div class="lb-trans"><p>Nektar Therapeutics 的股票在周四交易中下跌了$2.97，报$70.36。该公司的交易量为 963,157 股，而其平均交易量为 1,172,891 股。该股票的市值为 14.3 亿美元，市盈率为-8.83，贝塔值为 1.17。Nektar Therapeutics 的 1 年最低价为$6.45，1 年最高价为$75.67。该公司的 50 日简单移动平均线为$52.34，200 日简单移动平均线为$52.62。</p>
</div><h2>Insider Buying and Selling at Nektar Therapeutics</h2>
<div class="lb-trans"><h2>Nektar Therapeutics 的内部买卖</h2>
</div><p>In other news, insider Jonathan Zalevsky sold 3,867 shares of the firm's stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $35.67, for a total transaction of $137,935.89. Following the completion of the transaction, the insider directly owned 21,354 shares in the company, valued at $761,697.18. This trade represents a 15.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Howard W. Robin sold 423 shares of the business's stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $73.00, for a total value of $30,879.00. Following the completion of the sale, the chief executive officer owned 75,489 shares in the company, valued at $5,510,697. This represents a 0.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 4,470 shares of company stock valued at $181,955. Company insiders own 5.25% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，内部人士 Jonathan Zalevsky 于 1 月 20 日（星期二）出售了该公司 3867 股股票。股票以平均价格$35.67 出售，总交易额为$137,935.89。交易完成后，该内部人士直接持有公司 21,354 股，价值$761,697.18。这笔交易代表其持股减少了 15.33%。该交易已在 SEC 的备案中披露，相关信息可在 SEC 网站上找到。此外，首席执行官 Howard W. Robin 于 2 月 18 日（星期三）出售了 423 股公司的股票。股票以平均价格$73.00 出售，总价值为$30,879.00。交易完成后，首席执行官持有公司 75,489 股，价值$5,510,697。这代表其持股减少了 0.56%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士已出售 4470 股公司股票，价值$181,955。公司内部人士持有公司股票的 5.25%。</p>
</div><h2>Institutional Trading of Nektar Therapeutics</h2>
<div class="lb-trans"><h2>Nektar Therapeutics 的机构交易</h2>
</div><ul>
<li>Biotech Catalyst Alert: NKTR, CDTX &amp; WGS Rallying With Big Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技催化剂警报：NKTR、CDTX 和 WGS 大幅上涨</li>
</ul>
</div><p>Hedge funds have recently made changes to their positions in the business. Virtu Financial LLC purchased a new position in shares of Nektar Therapeutics in the fourth quarter valued at approximately $584,000. Invesco Ltd. lifted its holdings in Nektar Therapeutics by 106.3% during the 4th quarter. Invesco Ltd. now owns 468,159 shares of the biopharmaceutical company's stock worth $19,794,000 after buying an additional 241,262 shares in the last quarter. Creek Drive Management Group LLC purchased a new position in Nektar Therapeutics in the 4th quarter valued at approximately $7,843,000. KVP Capital Advisors LP purchased a new position in Nektar Therapeutics in the 4th quarter valued at approximately $1,137,000. Finally, XTX Topco Ltd grew its stake in shares of Nektar Therapeutics by 22.0% in the fourth quarter. XTX Topco Ltd now owns 7,196 shares of the biopharmaceutical company's stock worth $304,000 after acquiring an additional 1,299 shares in the last quarter. Institutional investors and hedge funds own 75.88% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金最近对该公司的持仓进行了调整。Virtu Financial LLC 在第四季度购买了 Nektar Therapeutics 的新头寸，价值约为 584,000 美元。Invesco Ltd.在第四季度将其在 Nektar Therapeutics 的持股增加了 106.3%。Invesco Ltd.现在拥有 468,159 股该生物制药公司的股票，价值$19,794,000，此前在上个季度又购买了 241,262 股。Creek Drive Management Group LLC 在第四季度购买了 Nektar Therapeutics 的新头寸，价值约为 7,843,000 美元。KVP Capital Advisors LP 在第四季度购买了 Nektar Therapeutics 的新头寸，价值约为 1,137,000 美元。最后，XTX Topco Ltd 在第四季度将其在 Nektar Therapeutics 的持股增加了 22.0%。XTX Topco Ltd 现在拥有 7,196 股该生物制药公司的股票，价值$304,000，此前在上个季度又收购了 1,299 股。机构投资者和对冲基金持有公司 75.88% 的股票。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师的看法</h2>
</div><p>NKTR has been the subject of several analyst reports. HC Wainwright increased their price target on shares of Nektar Therapeutics from $135.00 to $165.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, February 10th. Piper Sandler reaffirmed an &#34;overweight&#34; rating and set a $105.00 price target on shares of Nektar Therapeutics in a research report on Monday, January 26th. Jefferies Financial Group reiterated a &#34;buy&#34; rating on shares of Nektar Therapeutics in a research report on Wednesday, December 17th. Weiss Ratings reissued a &#34;sell (e+)&#34; rating on shares of Nektar Therapeutics in a research note on Monday, December 29th. Finally, BTIG Research upped their price target on Nektar Therapeutics from $118.00 to $151.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, February 10th. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $126.29.</p>
<div class="lb-trans"><p>NKTR 已成为几份分析师报告的主题。HC Wainwright 在 2 月 10 日（星期二）的研究报告中将 Nektar Therapeutics 的目标股价从$135.00 上调至$165.00，并给予该公司 “买入” 评级。Piper Sandler 在 1 月 26 日（星期一）的研究报告中重申了 “增持” 评级，并设定了 Nektar Therapeutics 的目标股价为$105.00。Jefferies Financial Group 在 12 月 17 日（星期三）的研究报告中重申了对 Nektar Therapeutics 的 “买入” 评级。Weiss Ratings 在 12 月 29 日（星期一）的研究报告中重新发布了对 Nektar Therapeutics 的 “卖出（e+）” 评级。最后，BTIG Research 在 2 月 10 日（星期二）的研究报告中将 Nektar Therapeutics 的目标股价从$118.00 上调至$151.00，并给予该公司 “买入” 评级。八位投资分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat，该公司目前的平均评级为 “适度买入”，共识目标价为$126.29。</p>
</div><ul>
<li>Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?</li>
</ul>
<div class="lb-trans"><ul>
<li>Nektar 因药物试验数据上涨 157%——还能更高吗？</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Analysis on NKTR</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 NKTR 股票分析</strong></p>
</div><h2>Trending Headlines about Nektar Therapeutics</h2>
<div class="lb-trans"><h2>关于 Nektar Therapeutics 的热门头条</h2>
</div><p>Here are the key news stories impacting Nektar Therapeutics this week:</p>
<div class="lb-trans"><p>以下是本周影响 Nektar Therapeutics 的主要新闻故事：</p>
</div><ul>
<li>Neutral Sentiment: Q4 / FY2025 results: Nektar reported cash &amp; marketable securities of $245.8M at 12/31/25 vs. $269.1M a year earlier — a drop that highlights limited liquidity as the company advances programs but is not, by itself, catastrophic. Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results</li>
<li>Negative Sentiment: Class action filed: A securities class action was filed in the N.D. California alleging misstatements between Feb 26, 2025 and Dec 15, 2025 — this creates potential future liability, discovery risk, management distraction and reputational damage. Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers - NKTR</li>
<li>Negative Sentiment: Multiple law‑firms and investigators are soliciting investors and opening probes (Glancy, Faruqi, Bernstein, Robbins, Rosen, Frank R. Cruz, etc.), amplifying sell pressure and signaling that litigation activity will continue. These notices often lead to lead‑plaintiff competition and increased litigation costs. Representative notices: Securities Fraud Investigation Into Nektar Therapeutics (NKTR) AnnouncedSecurities Fraud Investigation Into Nektar Therapeutics (NKTR) Announced - Frank R. Cruz</li>
<li>Negative Sentiment: Ongoing publicity about the litigation wave: several additional reminders and alerts from firms (Faruqi, Bernstein, Robbins, Rosen) keep the issue visible to retail and institutional holders and may prolong volatility. Examples: Pomerantz Law Firm AnnouncementFaruqi &amp; Faruqi Reminder</li>
<li>Negative Sentiment: Market commentary: Analysts and media explain downward moves and link them to the filings and prior clinical disclosures (which investors are scrutinizing), reinforcing negative sentiment. Why Nektar Therapeutics’s (NKTR) Stock Is Down 8.32%</li>
</ul>
<div class="lb-trans"><ul>
<li>中性情绪：2025 财年第四季度业绩：Nektar 报告截至 2025 年 12 月 31 日的现金及可交易证券为 2.458 亿美元，较去年同期的 2.691 亿美元下降——这一下降突显了公司在推进项目时流动性有限，但本身并不构成灾难。Nektar Therapeutics 发布 2025 年第四季度及全年财务业绩</li>
<li>消极情绪：集体诉讼已提起：在加州北区提起了一项证券集体诉讼，指控在 2025 年 2 月 26 日至 2025 年 12 月 15 日期间存在虚假陈述——这可能导致未来的潜在责任、调查风险、管理分心和声誉损害。Pomerantz 律师事务所宣布对 Nektar Therapeutics, Inc.及部分高管提起集体诉讼 - NKTR</li>
<li>消极情绪：多家律师事务所和调查人员正在招募投资者并展开调查（Glancy, Faruqi, Bernstein, Robbins, Rosen, Frank R. Cruz 等），加大了卖压，并表明诉讼活动将持续。这些通知通常会导致首席原告竞争和诉讼成本增加。代表性通知：对 Nektar Therapeutics (NKTR) 的证券欺诈调查已宣布</li>
<li>消极情绪：关于诉讼潮的持续宣传：多家律师事务所（Faruqi, Bernstein, Robbins, Rosen）发出的额外提醒和警报使这一问题对零售和机构持有者保持可见，可能延长波动性。示例：Pomerantz 律师事务所公告 Faruqi &amp; Faruqi 提醒</li>
<li>消极情绪：市场评论：分析师和媒体解释了股价下跌的原因，并将其与诉讼和先前的临床披露联系起来（投资者正在仔细审查），进一步强化了消极情绪。为什么 Nektar Therapeutics (NKTR) 的股票下跌了 8.32%</li>
</ul>
</div><h2>Nektar Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Nektar Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Nektar Therapeutics NASDAQ: NKTR is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body's immune system to treat cancer and other serious diseases.</p>
<div class="lb-trans"><p>Nektar Therapeutics（纳斯达克：NKTR）是一家生物制药公司，致力于通过其专有的化学和免疫学平台发现和开发新型药物候选者。该公司专注于聚合物结合技术，使现有药物的长效版本得以创造，并专注于 T 细胞调节疗法，旨在利用身体的免疫系统治疗癌症和其他严重疾病。</p>
</div><p>Nektar's product portfolio and pipeline include a range of clinical-stage and partnered programs.</p>
<div class="lb-trans"><p>Nektar 的产品组合和管道包括一系列临床阶段和合作项目。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Nektar Therapeutics</li>
<li>The $20 Trillion Discovery Beneath the Waves</li>
<li>The largest IPO in history is coming</li>
<li>Trump's NEW Executive Order - BIG Changes Coming to Retirement Accounts</li>
<li>Only 500 people today…</li>
<li>Central banks just did something they haven’t done since 1967</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Nektar Therapeutics</li>
<li>20 万亿美元的发现隐藏在海洋之下</li>
<li>历史上最大的 IPO 即将到来</li>
<li>特朗普的新行政命令 - 退休账户将迎来重大变化</li>
<li>今天只有 500 人……</li>
<li>中央银行刚刚做了一件自 1967 年以来未曾做过的事情</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TktUUg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=NKTR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Nektar Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Nektar Therapeutics 吗？</h2>
</div><p>Before you consider Nektar Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Nektar Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nektar Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Nektar Therapeutics 并不在名单上。</p>
</div><p>While Nektar Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Nektar Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Nektar Therapeutics (NASDAQ:NKTR) Releases Earnings Results, Beats Expectations By $0.91 EPS

Market Beat

内克塔治疗公司（NASDAQ:NKTR）公布了财报，每股收益超出预期 0.91 美元